Hildur Helgadottir, MD, PhD, Karolinska University Hospital, Stockholm, Sweden, shares insights from a nationwide registry-based study that examined survival outcomes in patients with stage III cutaneous malignant melanoma diagnosed before and after the introduction of adjuvant treatment in mid-2018. The study focused on sentinel node-positive patients and tracked overall survival (OS) in both pre- and post-2018 cohorts. With a median follow-up of three years in the post-cohort, no significant difference in OS was observed between the two groups, suggesting that adjuvant treatment has yet to show a clear survival benefit in these patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
